Ro Partners with Amgen to Use Real-World Data to Tackle GLP-1 Access Barriers in Obesity Care

New updates have been reported about Ro.

Ro has entered a research collaboration with Amgen that positions its nationwide direct-to-patient platform at the center of efforts to understand and reduce barriers to accessing GLP-1 obesity treatments. Using Ro’s de-identified real-world data from treatment-seeking patients, the partners will analyze how individuals and providers navigate insurance coverage, prior authorization requirements, and other obstacles that limit uptake of evidence-based obesity care, with the goal of informing new tools, care models, and potentially broader market access. Ro CEO and co-founder Zach Reitano said the work is aimed at moving beyond small-scale impact by generating insights that can support more personalized patient guidance and help unlock access for millions of clinically eligible Americans who currently face coverage and affordability challenges.

The research specifically targets real-world GLP-1 coverage patterns and the dynamics of prior authorizations, going beyond policy-level analysis to examine what actually happens when patients pursue therapy through a digital, integrated care platform. Findings are expected to help patients and providers better understand payer criteria, pinpoint gaps in coverage, and identify strategies to secure appropriate therapies, which could strengthen Ro’s value proposition in obesity and related cardiometabolic conditions as GLP-1s reshape the treatment landscape. Amgen’s observational research team, led by vice president Brian Bradbury, highlighted the collaboration as a way to translate Ro’s ecosystem data into future therapy development and care delivery innovations. Strategically, the initiative reinforces Ro’s positioning as a data-rich, nationwide telehealth, labs, and pharmacy provider and underscores its role as an evidence-generation partner for life sciences companies seeking to improve patient outcomes in high-growth therapeutic areas.